《新股表現》友芝友生物-B(02496.HK)上市翌日反覆走高 午後曾升逾18%
友芝友生物-B(02496.HK)繼上日(25日)首掛牌險守招股價16元後,今日(26日)高開1.3%,隨後升幅輾轉擴大,午後曾升18.1%,最高見18.9元。現報18.6元,升16.25%,成交73.18萬股,涉資1,278.41萬元。
友芝友是一家致力於開發用於治療癌症相關併發症、癌症及老年性眼科疾病的基於雙特異性抗體(BsAb)療法的生物技術公司,並已設計和開發了七種臨床階段候選藥物管線,包括核心產品M701。是次公開發售獲約12.8倍超購,認購一手中籤率18%;股份以招股範圍(16至20元)下限定價,料集資淨額約1.21億元。上市獨家保薦人中信建投國際。
同於昨日上市新股樂艙物流(02490.HK)今日偏軟,最低見4.9元。現報4.98元,跌2.35%,成交15.7萬股,涉資78.06萬元。現價較上市價5.13元低2.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.